Company Overview of Advaxis, Inc.
Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. Its Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. The company’s platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. It has approximately ...
305 College Road East
Princeton, NJ 08540
Founded in 2002
Key Executives for Advaxis, Inc.
Chief Executive Officer
Total Annual Compensation: $312.5K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $371.7K
Total Annual Compensation: $304.2K
Compensation as of Fiscal Year 2013.
Advaxis, Inc. Key Developments
Japan Patent Office Issues Advaxis, Inc. a Notice of Allowance for Two Patent Applications Covering its Cancer Immunotherapy Platform Technology
Apr 14 14
Advaxis, Inc. announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030. Including these patents, Advaxis now has well over 40 patents issued and over 40 patents pending worldwide, all covering both core methodology and other aspects of proprietary immunotherapy technology platform. One of the patent applications allowed by the Japan Patent Office covers Advaxis's immunotherapy treatments targeting factors that are essential for tumors or metastases to form new blood vessels (angiogenesis) or that are expressed by tumor blood vessels. Inhibiting a tumor's blood supply is necessary to prevent tumor growth. The claims allowed under this patent application cover multiple targets associated with angiogenesis that can be targeted at the same time in humans as well as animals. These targets include, but are not limited to, HER2 and VEGFr2. In addition, the claims also cover endoglin fragments (CD105A and CD105B) used to target formation of new tumor blood vessels. The second patent application that has now been allowed by the Japan Patent Office covers the form of a recombinant attenuated auxotrophic Listeria having specific mutations conferring attenuation along with plasmid that complements the genomic mutation and also expresses a protein antigen fused to highly immunogenic Listeria peptides or other strongly immunogenic pathogen-associated peptide sequences. The claims allowed under this patent application protect key elements of Advaxis's proprietary immunotherapy platform technology in Japan.
Advaxis, Inc. Announces Executive Changes
Mar 24 14
Advaxis, Inc. announced that it has appointed Sara Bonstein to the position of Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems, and Johnson & Johnson. While at Eli Lilly & Company, Ms. Bonstein was a Six Sigma Champion and Black Belt, leading multiple projects relating to clinical research, project management, finance, manufacturing, and commercial sales. Advaxis also announced the departure of Mark Rosenblum, Chief Financial Officer, effective March 24, 2014 to pursue other opportunities.
Advaxis, Inc., Aratana Therapeutics, Inc. - Special Call
Mar 20 14
To discuss global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer
Similar Private Companies By Industry
Recent Private Companies Transactions